VJOncology is committed to improving our service to you

ESMO 2020 | Immunotherapy trial updates in NSCLC from ESMO 2020

VJOncology is committed to improving our service to you

Roy Herbst

Roy Herbst, MD, PhD, FACP, FASCO, Yale University, New Haven, CT, discusses three abstracts presented at the European Society of Medical Oncology (ESMO) 2020 virtual congress, including 5-year overall survival data from the KEYNOTE-024 (NCT02142738) study evaluating pembrolizumab versus chemotherapy in non-small cell lung cancer (NSCLC), the results from the EMPOWER-Lung 1 study investigating cemiplimab monotherapy and finally, the first analysis of the PIONeeR study (NCT03833440) in NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter